2021
*) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number...
10 November, 2021
FluoGuide selects lung cancer as the next indication for FG001 and will initiate phase II trial in the beginning of 2022
FluoGuide now broadens the clinical potential for fluorescence-guided cancer surgery with FG001 to include the first prevalent indication...
9 November, 2021
Publication of a case report showing first promising clinical data on FG001s use in treatment of meningioma brain tumor
FG001 is currently in clinical investigation at Rigshospitalet, Denmark in a phase I/II trial in patients with High Grade Glioma undergoing...
5 November, 2021
Financial calendar 2022 for FluoGuide, and release of the Q3 report 2021 is moved to 15[th] of November 2021
Financial calendar for 2022 The planned release of the Q3 financial report 2021 is moved from 24th November to 15th November 2021...
1 November, 2021
FluoGuide initiates preclinical development with FG002
The initiation of the preclinical development of FG002 broadens FluoGuide’s portfolio of uPAR-targeted products with features...
12 October, 2021
Redeye initiates commissioned research on FluoGuide
Starting today, Redeye has initiated its commissioned research, meaning that Redeye will continuously monitor and analyze FluoGuide’s...
It is an important milestone for FluoGuide to now be able to demonstrate that FG001 is safe and well tolerated in patients undergoing...
14 September, 2021
Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares
“Due to the success of FluoGuide, I have to pay tax on my shareholdings of FluoGuide and I have decided to finance this by selling...
FluoGuide is conducting a clinical phase I/II trial evaluating safety and efficacy of its lead asset, FG001, in patients with aggressive...